Veltuzumab clinical trials
Also written IMMU-106 and hA20.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2004
How each study uses veltuzumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2004 (2)
| Year | Studies |
|---|---|
| 2004 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 2
Gilead Sciences (4) · Beth Christian (1) · Weill Medical College of Cornell University (1) · Takeda (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses veltuzumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's LymphomaCompletedPhase 1/2Gilead SciencesNCT00596804Written as veltuzumab
- Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's LymphomaCompletedPhase 1/2Gilead SciencesNCT00285428Written as hA20-humanized anti-CD20 antibody
- Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLLCompletedPhase 1/2Gilead SciencesNCT00546793Written as veltuzumab
- Study of Veltuzumab (hA20) at Different Doses in Patients With ITPTerminatedPhase 1/2Gilead SciencesNCT00547066Written as veltuzumab
- Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular LymphomaTerminatedPhase 1/2Weill Medical College of Cornell UniversityNCT01147393Written as veltuzumab
- Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaCompletedPhase 1/2Beth ChristianNCT00989586Written as veltuzumab
- VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid ArthritisTerminatedPhase 2TakedaNCT01390545Written as Veltuzumab
Given beside what is tested · 1 — veltuzumab is usual care or a partner of the new treatment
Codes
What other systems call veltuzumab · ClinicalTrials.gg INT004720
- MeSH (NLM) C493846veltuzumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) BPD4DGQ314VELTUZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q4009438VeltuzumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C48406VeltuzumabOne source FDA
- DrugBank DB05656One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C493846 | veltuzumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | BPD4DGQ314 | VELTUZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q4009438 | Veltuzumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C48406 | Veltuzumab | One source FDA |
| DrugBank | DB05656 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.